英伯克斯生物科技

最新新闻

• Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $325
  \u5e02\u573a\u8d44\u8baf · 2026/8/21
• 评级变动
  Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Raises Target Price to $300
  \u5e02\u573a\u8d44\u8baf · 2026/4/22
• Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), Inhibrx Biosciences Inc (INBX) and Circle Internet Group, Inc. Class A (CRCL)
  TipRanks · 2026/9/9
• LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $230
  \u5e02\u573a\u8d44\u8baf · 2026/9/8
• 评级变动
  Stifel Initiates Inhibrx Biosciences(INBX.US) With Buy Rating, Announces Target Price $150
  \u5e02\u573a\u8d44\u8baf · 2026/4/17
• 评级变动
  JMP Securities Maintains Inhibrx Biosciences(INBX.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2025/3/19
• H.C. Wainwright Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $245
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Raises Target Price to $230
  \u5e02\u573a\u8d44\u8baf · 2026/5/11
• 评级变动
  LifeSci Capital Initiates Inhibrx Biosciences(INBX.US) With Buy Rating, Announces Target Price $200
  \u5e02\u573a\u8d44\u8baf · 2026/4/24
• 公司公告
  Inhibrx: Inhibrx, Inc. - Distribution Option Symbol: INBX New Symbol: INBX1
  OCC · 2024/5/30
• 评级变动
  LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $200
  \u5e02\u573a\u8d44\u8baf · 2026/4/26
• 评级变动
  Citizens JMP Maintains Inhibrx Biosciences(INBX.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2025/5/16
• 评级变动
  Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS), Fractyl Health, Inc. (GUTS) and Inhibrx Biosciences Inc (INBX)
  TipRanks · 2026/5/11
• 评级变动
  Analysts Are Bullish on These Healthcare Stocks: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Inhibrx (INBX)
  TipRanks · 2023/11/20
• H.C. Wainwright Initiates Inhibrx Biosciences(INBX.US) With Buy Rating, Announces Target Price $245
  \u5e02\u573a\u8d44\u8baf · 2026/8/25
• 评级变动
  Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Raises Target Price to $325
  \u5e02\u573a\u8d44\u8baf · 2026/5/15

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。